Clinuvel Stock
StockStockPrice
Historical dividends and forecast
Clinuvel has so far distributed $0.034 in 2024. The next dividend will be paid on 20.09.2025
CHART BY
Frequently asked questions
What is Clinuvel's market capitalization?
What is Clinuvel's Price-to-Earnings (P/E) ratio?
What is the Earnings Per Share (EPS) for Clinuvel?
What are the analyst ratings and target price for Clinuvel's stock?
What is Clinuvel's revenue over the trailing twelve months?
What is the EBITDA for Clinuvel?
What is the free cash flow of Clinuvel?
What is the 5-year beta of Clinuvel's stock?
How many employees does Clinuvel have, and what sector and industry does it belong to?
What is the free float of Clinuvel's shares?
Financials
Market Cap
$445.76M5Y beta
0.66EPS (TTM)
$0.458Free Float
41.44MP/E ratio (TTM)
19.43Revenue (TTM)
$62.39MEBITDA (TTM)
$38.03MFree Cashflow (TTM)
$18.95MPricing
Analyst Ratings
The price target is $17.25 and the stock is covered by 4 analysts.
Buy
4
Hold
0
Sell
0
Information
Clinuvel Pharmaceuticals Limited is an Australia-based global specialty pharmaceutical company. The Company is focused on developing and commercializing treatments for patients with genetic, metabolic, systemic, and life-threatening, acute disorders, as well as healthcare solutions for specialized populations. Its lead therapy, SCENESSE (afamelanotide 16mg), is approved for commercial distribution in Europe, the USA, Israel, and Australia as the first systemic photoprotective drug for the prevention of phototoxicity (anaphylactoid reactions and burns) in adult patients with erythropoietic protoporphyria (EPP). The Company’s pharmaceuticals product development includes PRENUMBRA and NEURACTHEL. Its PhotoCosmetics product development includes CYACELLE and DNA Repair Assist and Melanogenesis. PRENUMBRA is a formulation of afamelanotide designed to provide a flexible dose in identified patient groups. NEURACTHEL is a novel formulation of the melanocortin adrenocorticotropic hormone (ACTH).
16
Biotechnology & Drugs
Health Care
Identifier
ISIN
Primary Ticker